Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsResearchers investigated five BRAFV600E melanoma cell lines derived from drug-naïve tumor specimens to assess cell death response to encorafenib, a recently FDA-approved BRAFV600E inhibitor.
[Cancer Letters]
6807162 {6807162:N8NRA4GI} apa 50 1 156937 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-591ce090c46fdf42b9d4947328bfe955%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22N8NRA4GI%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hartman%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHartman%2C%20M.%20L.%2C%20Gajos-Michniewicz%2C%20A.%2C%20Talaj%2C%20J.%20A.%2C%20Mielczarek-Lewandowska%2C%20A.%2C%20%26amp%3B%20Czyz%2C%20M.%20%282020%29.%20BH3%20mimetics%20potentiate%20pro-apoptotic%20activity%20of%20encorafenib%20in%20BRAFV600E%20melanoma%20cells.%20%3Ci%3ECancer%20Letters%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canlet.2020.11.036%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canlet.2020.11.036%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3DN8NRA4GI%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22BH3%20mimetics%20potentiate%20pro-apoptotic%20activity%20of%20encorafenib%20in%20BRAFV600E%20melanoma%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariusz%20L.%22%2C%22lastName%22%3A%22Hartman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Gajos-Michniewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julita%20A.%22%2C%22lastName%22%3A%22Talaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleksandra%22%2C%22lastName%22%3A%22Mielczarek-Lewandowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malgorzata%22%2C%22lastName%22%3A%22Czyz%22%7D%5D%2C%22abstractNote%22%3A%22BRAFV600-%20and%20MEK1%5C%2F2-targeting%20therapies%20rarely%20produce%20durable%20response%20in%20melanoma%20patients.%20We%20investigated%20five%20BRAFV600E%20melanoma%20cell%20lines%20derived%20from%20drug-na%5Cu00efve%20tumor%20specimens%20to%20assess%20cell%20death%20response%20to%20encorafenib%20%28Braftovi%29%2C%20a%20recently%20FDA-approved%20BRAFV600%20inhibitor.%20Drug-na%5Cu00efve%20cell%20lines%20%28i%29%20did%20not%20harbor%20damaging%20alterations%20in%20genes%20encoding%20core%20apoptotic%20machinery%2C%20but%20they%20differed%20in%20%28ii%29%20mitochondrial%20priming%20as%20demonstrated%20by%20whole-cell%20BH3%20profiling%2C%20and%20%28iii%29%20levels%20of%20selected%20anti-apoptotic%20proteins.%20Encorafenib%20modulated%20the%20balance%20between%20apoptosis-regulating%20proteins%20as%20it%20upregulated%20BIM%20and%20BMF%2C%20and%20attenuated%20NOXA%2C%20but%20did%20not%20affect%20the%20levels%20of%20pro-survival%20proteins%20except%20for%20MCL-1%20and%20BCL-XL%20in%20selected%20cell%20lines.%20Induction%20of%20apoptosis%20could%20be%20predicted%20using%20Dynamic%20BH3%20profiling.%20The%20extent%20of%20apoptosis%20was%20dependent%20on%20both%20%28i%29%20cell-intrinsic%20proximity%20to%20the%20apoptotic%20threshold%20%28initial%20mitochondrial%20priming%29%20and%20%28ii%29%20the%20abundance%20of%20encorafenib-induced%20BIM%20%28iBIM%3B%20drug-induced%20change%20in%20priming%29.%20While%20co-inhibition%20of%20MCL-1%20and%20BCL-XL%5C%2FBCL-2%20was%20indispensable%20for%20apoptosis%20in%20drug-na%5Cu00efve%20cells%2C%20encorafenib%20altered%20cell%20dependence%20to%20MCL-1%2C%20and%20reliance%20on%20BCL-XL%5C%2FBCL-2%20was%20additionally%20found%20in%20cell%20lines%20that%20were%20highly%20primed%20to%20apoptosis%20by%20encorafenib.%20This%20translated%20into%20robust%20apoptosis%20when%20encorafenib%20was%20combined%20with%20selective%20BH3%20mimetics.%20Our%20study%20provides%20a%20mechanistic%20insight%20into%20the%20role%20of%20proteins%20from%20the%20BCL-2%20family%20in%20melanoma%20cell%20response%20to%20targeted%20therapy%2C%20and%20presents%20preclinical%20evidence%20that%20%28i%29%20MCL-1%20is%20a%20druggable%20target%20to%20potentiate%20encorafenib%20activity%2C%20whereas%20%28ii%29%20pharmacological%20inhibition%20of%20BCL-XL%5C%2FBCL-2%20might%20be%20relevant%20but%20only%20for%20a%20narrow%20group%20of%20encorafenib-treated%20patients.%22%2C%22date%22%3A%22November%2028%2C%202020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canlet.2020.11.036%22%2C%22ISSN%22%3A%220304-3835%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0304383520306352%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222020-12-04T22%3A29%3A14Z%22%7D%7D%5D%7D
Hartman, M. L., Gajos-Michniewicz, A., Talaj, J. A., Mielczarek-Lewandowska, A., & Czyz, M. (2020). BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells. Cancer Letters. https://doi.org/10.1016/j.canlet.2020.11.036 Cite
